SCHEMBL1625401

SCHEMBL1625401

CCOC(=O)C(C(=O)OCC)C(=O)C(C)(C)c1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 4/20 0.42
LMNA P02545 4/20 0.41
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
GLA P06280 1/20 0.37
RIPK1 Q13546 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
EDNRB P24530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627104 0.86 ALDH1A1 (0.46) MAPTPOLBSMN1; SMN2ALDH1A1HPGD
SCHEMBL1625659 0.83 ALDH1A1 (0.41) LMNAMAPTSMN1; SMN2RIPK1ALDH1A1
SCHEMBL1626115 0.83 MAPT (0.42) LMNAMAPTSMN1; SMN2TRPM8ALDH1A1
SCHEMBL1626934 0.82 MAPT (0.42) LMNAMAPTPOLBSMN1; SMN2TDP1
SCHEMBL1627161 0.82 PIN1 (0.46) MAPTPOLBSMN1; SMN2TDP1ALDH1A1
SCHEMBL1625483 0.82 AKR1C3 (0.38) KCNN4POLBRIPK1ALDH1A1HPGD
SCHEMBL1626441 0.78 AKR1C3 (0.39) LMNAMAPTSMN1; SMN2TSHRNPSR1
SCHEMBL1626109 0.78 L3MBTL1 (0.40) LMNASMN1; SMN2TSHRHTTNPC1
SCHEMBL1626748 0.77 NPSR1 (0.46) LMNAMAPTPOLBSMN1; SMN2ALDH1A1
SCHEMBL1626434 0.76 AURKA (0.44) MAPTPOLBSMN1; SMN2TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN KCNN4 4743/4885LMNA 1715/4885MAPT 4316/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN KCNN4 4743/4885LMNA 1715/4885MAPT 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.